1. In Vivo
  2. >>Leadership
  3. >>C-Suite Speaks

Building A US Business: Celltrion’s New CCO Talks Strategy

Biosimilars Specialist Moves To Direct Sales Model In US With Three Key Launches

 
• By Dave Wallace

With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks about how the firm is gearing up to launch three key products.

Jigsaw puzzle of US flag
Tom Nusbickel has been piecing together Celltrion’s US operation • Source: Shutterstock

Celltrion is not new to the US biosimilars market. For years, the company has partnered with other leading firms – including Pfizer Inc. and Teva Pharmaceutical Industries Ltd. – to market its biosimilars in the US, notching up achievements that have included launching the first US biosimilar monoclonal antibody, with Inflectra (infliximab-dyyb), as well as offering the first Rituxan (rituximab) rival to boast a key rheumatoid arthritis indication. (Also see "Teva And Celltrion Gain Arthritis Advantage On Rituximab" - Generics Bulletin, 6 May, 2020.)

However, a significant change is now on the horizon for Celltrion, as it transitions to a direct sales model for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from C-Suite Speaks

Podcast: Poolbeg CEO On The Biotech’s Big Bet On Small Molecules

 
• By Jo Shorthouse

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

More from Leadership

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By David Wild

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.